{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:12:29Z","timestamp":1755216749942,"version":"3.43.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>A 17-year-old previously healthy female developed posterior reversible encephalopathy syndrome 1 week after etonogestrel implantation. She had a previous etonogestrel implant removed 4 months prior after unrelenting abdominal pain and hyponatremia with a negative workup for other etiologies, including hypercoagulable disorders and malignancy. This second insertion and resulting hospitalization allowed for the diagnosis of acute intermittent porphyria (AIP) to be confirmed. Progesterone can induce enzymatic activity upstream of porphobilinogen deaminase, the enzyme implicated in AIP, resulting in build-up of toxic metabolites. AIP requires high clinical suspicion for diagnosis but should be considered when hormonal triggers lead to unexplained neurovisceral symptoms.<\/jats:p>","DOI":"10.1097\/mph.0000000000002920","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:09:08Z","timestamp":1720195748000},"page":"319-321","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Onset of Acute Intermittent Porphyria After Etonogestrel Implant Insertion: A Case Report"],"prefix":"10.1097","volume":"46","author":[{"given":"Justin","family":"Furcich","sequence":"first","affiliation":[{"name":"University of Minnesota Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Boucher","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology\/Oncology"},{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Grace","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hospital Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bpg.2004.10.006","article-title":"Acute intermittent porphyria","volume":"19","author":"Herrick","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/humu.23067","article-title":"Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease","volume":"37","author":"Chen","year":"2016","journal-title":"Hum Mutat"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/TACG.S48605","article-title":"An update of clinical management of acute intermittent porphyria","volume":"8","author":"Pischik","year":"2015","journal-title":"Appl Clin Genet"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"439","DOI":"10.7326\/0003-4819-142-6-200503150-00010","article-title":"Recommendations for the diagnosis and treatment of the acute porphyrias [published correction appears in Ann Intern Med. 2005 Aug 16;143(4):316]","volume":"142","author":"Anderson","year":"2005","journal-title":"Ann Intern Med"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1073\/pnas.0401845101","article-title":"Identification of the xenosensors regulating human 5-aminolevulinate synthase","volume":"101","author":"Podvinec","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ana.410020415","article-title":"delta-Aminolevulinic acid: influences on synaptic GABA receptor binding may explain CNS symptoms of porphyria","volume":"2","author":"M\u00fcller","year":"1977","journal-title":"Ann Neurol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000330683","article-title":"Neurological complications of acute intermittent porphyria","volume":"66","author":"Kuo","year":"2011","journal-title":"Eur Neurol"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"598","DOI":"10.7326\/0003-4819-123-8-199510150-00006","article-title":"Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria","volume":"123","author":"Kupferschmidt","year":"1995","journal-title":"Ann Intern Med"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7326\/0003-4819-125-5-199609010-00023","article-title":"Cortical brain lesions in acute intermittent porphyria","volume":"125","author":"Sze","year":"1996","journal-title":"Ann Intern Med"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1472-8206.2000.tb00411.x","article-title":"Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies","volume":"14","author":"Benedetti","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/0003-4819-83-6-851","article-title":"Acute intermittent porphyria: clinical and selected research aspects","volume":"83","author":"Tschudy","year":"1975","journal-title":"Ann Intern Med"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1530\/eje.0.1410050","article-title":"Premenstrual attacks of acute intermittent porphyria: hormonal and metabolic aspects\u2014a case report","volume":"141","author":"De Block","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"R13-20250804","first-page":"337","article-title":"Etonogestrel (Implanon), another treatment option for contraception","volume":"33","author":"Maddox","year":"2008","journal-title":"P T"},{"issue":"pt 3","key":"R14-20250804","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0004563212474555","article-title":"Best practice guidelines on clinical management of acute attacks of porphyria and their complications","volume":"50","author":"Stein","year":"2013","journal-title":"Ann Clin Biochem"},{"key":"R15-20250804","first-page":"2","article-title":"Severe acute hyponatremia as an initial presentation of acute intermittent porphyria triggered by a subdermal etonogestrel implant","volume":"2","author":"Valente","year":"2016","journal-title":"J Nephrol Renal Ther"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2796.2003.01172.x","article-title":"Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden","volume":"254","author":"Andersson","year":"2003","journal-title":"J Intern Med"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archinte.1990.00390190115018","article-title":"A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria","volume":"150","author":"Anderson","year":"1990","journal-title":"Arch Intern Med"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3122\/jabfm.13.1.76","article-title":"Acute intermittent porphyria with seizure and paralysis in the puerperium","volume":"13","author":"Keung","year":"2000","journal-title":"J Am Board Fam Pract"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/19418744211073029","article-title":"Clinical challenges of acute porphyria in the young adult.","volume":"12","author":"Burns","year":"2022","journal-title":"Neurohospitalist"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.pharmthera.2011.06.001","article-title":"Drugs in porphyria: from observation to a modern algorithm-based system for the prediction of porphyrogenicity","volume":"132","author":"Hift","year":"2011","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:05:02Z","timestamp":1754337902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002920","relation":{},"ISSN":["1077-4114"],"issn-type":[{"type":"print","value":"1077-4114"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"2024-05-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}